[The prevention of cytomegalovirus infection and disease by administration of biological products].

Symptomatic cytomegalovirus(CMV) infection is a serious complication in organ transplant and bone marrow transplant recipients. CMV immunoglobulin is available to prevent CMV disease in renal transplant and bone marrow transplant recipients, but not so efficacious in liver transplant and heart transplant recipients. Live CMV vaccine, Towne strain, is immunogenic in renal transplant recipients. Concerns about potential side effects of live-attenuated vaccine have stimulated the development of subunit vaccine. Several of CMV subunit vaccine are tested in animal models. Adoptive immunotherapy has been newly developed to prevent CMV disease in bone marrow transplant recipients. The suitable prevention for CMV infection and disease in accordance with the immunological status of transplant recipients will be established in the near future.